Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 222

1.

Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA.

Cancer Res. 2011 Aug 1;71(15):5081-9. doi: 10.1158/0008-5472.CAN-10-4668. Epub 2011 Jun 15.

PMID:
21676886
[PubMed - indexed for MEDLINE]
Free Article
2.

Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival.

Wong TF, Yoshinaga K, Monma Y, Ito K, Niikura H, Nagase S, Yamamoto M, Yaegashi N.

Int J Gynecol Cancer. 2011 Nov;21(8):1428-35. doi: 10.1097/IGC.0b013e31822d0eb2.

PMID:
21897267
[PubMed - indexed for MEDLINE]
3.

Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.

Yamadori T, Ishii Y, Homma S, Morishima Y, Kurishima K, Itoh K, Yamamoto M, Minami Y, Noguchi M, Hizawa N.

Oncogene. 2012 Nov 8;31(45):4768-77. doi: 10.1038/onc.2011.628. Epub 2012 Jan 16.

PMID:
22249257
[PubMed - indexed for MEDLINE]
4.

Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.

Zhan L, Zhang H, Zhang Q, Woods CG, Chen Y, Xue P, Dong J, Tokar EJ, Xu Y, Hou Y, Fu J, Yarborough K, Wang A, Qu W, Waalkes MP, Andersen ME, Pi J.

Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.

PMID:
22684020
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.

Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K, Kobayashi H, Otsuki Y, Nakayama S, Miyazaki K.

Mod Pathol. 2012 Feb;25(2):282-8. doi: 10.1038/modpathol.2011.161. Epub 2011 Nov 18.

PMID:
22101352
[PubMed - indexed for MEDLINE]
Free Article
6.

Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.

Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S.

Gastroenterology. 2008 Oct;135(4):1358-1368, 1368.e1-4. doi: 10.1053/j.gastro.2008.06.082. Epub 2008 Jul 3.

PMID:
18692501
[PubMed - indexed for MEDLINE]
7.

Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.

Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, Biswal S.

PLoS Med. 2006 Oct;3(10):e420.

PMID:
17020408
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds.

MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K, Hayes JD.

Carcinogenesis. 2009 Sep;30(9):1571-80. doi: 10.1093/carcin/bgp176. Epub 2009 Jul 16.

PMID:
19608619
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.

Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II.

Clin Cancer Res. 2010 Jul 15;16(14):3743-53. doi: 10.1158/1078-0432.CCR-09-3352. Epub 2010 Jun 9.

PMID:
20534738
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway.

Shim GS, Manandhar S, Shin DH, Kim TH, Kwak MK.

Free Radic Biol Med. 2009 Dec 1;47(11):1619-31. doi: 10.1016/j.freeradbiomed.2009.09.006. Epub 2009 Sep 12.

PMID:
19751820
[PubMed - indexed for MEDLINE]
11.

HMOX1 and NQO1 genes are upregulated in response to contact sensitizers in dendritic cells and THP-1 cell line: role of the Keap1/Nrf2 pathway.

Ade N, Leon F, Pallardy M, Peiffer JL, Kerdine-Romer S, Tissier MH, Bonnet PA, Fabre I, Ourlin JC.

Toxicol Sci. 2009 Feb;107(2):451-60. doi: 10.1093/toxsci/kfn243. Epub 2008 Nov 25.

PMID:
19033392
[PubMed - indexed for MEDLINE]
Free Article
12.

Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.

Shibata T, Saito S, Kokubu A, Suzuki T, Yamamoto M, Hirohashi S.

Cancer Res. 2010 Nov 15;70(22):9095-105. doi: 10.1158/0008-5472.CAN-10-0384. Epub 2010 Nov 9.

PMID:
21062981
[PubMed - indexed for MEDLINE]
Free Article
13.

Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway.

Yu M, Li H, Liu Q, Liu F, Tang L, Li C, Yuan Y, Zhan Y, Xu W, Li W, Chen H, Ge C, Wang J, Yang X.

Cell Signal. 2011 May;23(5):883-92. doi: 10.1016/j.cellsig.2011.01.014. Epub 2011 Jan 22.

PMID:
21262351
[PubMed - indexed for MEDLINE]
14.

Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.

Taguchi K, Motohashi H, Yamamoto M.

Genes Cells. 2011 Feb;16(2):123-40. doi: 10.1111/j.1365-2443.2010.01473.x. Review.

PMID:
21251164
[PubMed - indexed for MEDLINE]
15.

NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.

Hayes JD, McMahon M.

Trends Biochem Sci. 2009 Apr;34(4):176-88. doi: 10.1016/j.tibs.2008.12.008. Epub 2009 Mar 25. Review.

PMID:
19321346
[PubMed - indexed for MEDLINE]
16.

Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.

Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.

Biomed Pharmacother. 2009 Sep;63(8):553-60. doi: 10.1016/j.biopha.2008.04.006. Epub 2008 May 27.

PMID:
18571892
[PubMed - indexed for MEDLINE]
17.

Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells.

Li CQ, Kim MY, Godoy LC, Thiantanawat A, Trudel LJ, Wogan GN.

Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14547-51. doi: 10.1073/pnas.0907539106. Epub 2009 Aug 11.

PMID:
19706542
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA.

Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433. Epub 2012 Oct 8.

PMID:
23045278
[PubMed - indexed for MEDLINE]
19.

Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.

Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, Hirohashi S.

Cancer Res. 2008 Mar 1;68(5):1303-9. doi: 10.1158/0008-5472.CAN-07-5003.

PMID:
18316592
[PubMed - indexed for MEDLINE]
Free Article
20.

Dysfunctional Nrf2-Keap1 redox signaling in skeletal muscle of the sedentary old.

Safdar A, deBeer J, Tarnopolsky MA.

Free Radic Biol Med. 2010 Nov 30;49(10):1487-93. doi: 10.1016/j.freeradbiomed.2010.08.010. Epub 2010 Aug 11.

PMID:
20708680
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk